FDA Approves Merck ’s Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Appropriate Patients

KENILWORTH, N.J.--(BUSINESS WIRE) August 30, 2018 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Delstrigo, a once-daily fixed-dose combination...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news